{"id":"amlodipine-norvasc","safety":{"commonSideEffects":[{"rate":"1.5–4%","effect":"Peripheral edema"},{"rate":"7–16%","effect":"Headache"},{"rate":"4–6%","effect":"Flushing"},{"rate":"4–5%","effect":"Fatigue"},{"rate":"1–3%","effect":"Dizziness"},{"rate":"1–4%","effect":"Palpitations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amlodipine is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in the vasculature and heart. By preventing calcium influx into smooth muscle cells, it reduces vascular tone and peripheral resistance, leading to vasodilation and decreased blood pressure. It also has mild negative inotropic effects and reduces myocardial oxygen demand.","oneSentence":"Amlodipine blocks calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:20.706Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris (chronic stable angina and vasospastic angina)"}]},"trialDetails":[{"nctId":"NCT04040634","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-08","conditions":"Diabetes Mellitus, High Blood Pressure, Cardiovascular Diseases","enrollment":9476},{"nctId":"NCT07486453","phase":"PHASE1","title":"Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2026-03-09","conditions":"Primary Hypertension","enrollment":60},{"nctId":"NCT05293756","phase":"NA","title":"OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)","status":"RECRUITING","sponsor":"Case Western Reserve University","startDate":"2021-02-14","conditions":"Hypertension, Self-Management, Technology","enrollment":208},{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":"Intracerebral Hemorrhage","enrollment":140},{"nctId":"NCT07436104","phase":"PHASE4","title":"Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.","status":"COMPLETED","sponsor":"MAHAN Trust","startDate":"2004-01-01","conditions":"Hypertension (HTN), Diarrhea, Pneumonia","enrollment":72564},{"nctId":"NCT05312892","phase":"PHASE1, PHASE2","title":"Sympathetic Mechanisms in Obesity-Crossover Design","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-05-20","conditions":"Obesity, Hypertension","enrollment":12},{"nctId":"NCT05660083","phase":"PHASE2","title":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-01-12","conditions":"HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma","enrollment":36},{"nctId":"NCT06041529","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2023-10-18","conditions":"Essential Hypertension","enrollment":198},{"nctId":"NCT07099677","phase":"NA","title":"Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk","status":"RECRUITING","sponsor":"Abant Izzet Baysal University","startDate":"2025-08-01","conditions":"Hypertension, Fall Risk, Postural Balance","enrollment":186},{"nctId":"NCT05780710","phase":"NA","title":"OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake","status":"RECRUITING","sponsor":"Aktiia SA","startDate":"2023-06-29","conditions":"Hypertension","enrollment":35},{"nctId":"NCT04434664","phase":"PHASE4","title":"BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2021-12-01","conditions":"Heart Failure With Preserved Ejection Fraction, Hypertension","enrollment":50},{"nctId":"NCT05609513","phase":"NA","title":"Integration of Hypertension Management in HIV Care in Uganda","status":"COMPLETED","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2023-02-06","conditions":"HIV/AIDS, Hypertension","enrollment":87421},{"nctId":"NCT05370599","phase":"PHASE2","title":"Hypertension in Young Adults Trial","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2022-04-15","conditions":"Hypertension","enrollment":36},{"nctId":"NCT06236061","phase":"PHASE3","title":"Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-08","conditions":"Hypertension","enrollment":718},{"nctId":"NCT07327749","phase":"PHASE4","title":"Comparing Bisoprolol and Valsartan-Amlodipine for Hypertension","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2022-10-01","conditions":"Hypertension","enrollment":59},{"nctId":"NCT05593055","phase":"PHASE4","title":"Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-08-25","conditions":"Hypertension, Left Ventricular Hypertrophy","enrollment":75},{"nctId":"NCT07291375","phase":"EARLY_PHASE1","title":"Role of Amlodipine in Reduction of CIN","status":"NOT_YET_RECRUITING","sponsor":"Minia University","startDate":"2025-12-20","conditions":"Contrast-induced Nephropathy","enrollment":40},{"nctId":"NCT07075965","phase":"PHASE1","title":"Calcium Channel Blocker in Myotonic Dystrophy Type 1","status":"NOT_YET_RECRUITING","sponsor":"University of Rochester","startDate":"2026-12-07","conditions":"Myotonic Dystrophy 1","enrollment":20},{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT07259733","phase":"NA","title":"Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)","status":"RECRUITING","sponsor":"Instituto Dante Pazzanese de Cardiologia","startDate":"2023-07-15","conditions":"Apparent Resistant Hypertension, Hypertension, High Blood Pressure","enrollment":142},{"nctId":"NCT07241338","phase":"PHASE4","title":"Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity","status":"NOT_YET_RECRUITING","sponsor":"Jing Liu","startDate":"2025-11","conditions":"Hypertension","enrollment":104},{"nctId":"NCT07240909","phase":"PHASE4","title":"Antihypertensive Drug Selection Based on Hemodynamic Phenotypes","status":"NOT_YET_RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2026-01","conditions":"Hypertension","enrollment":240},{"nctId":"NCT07232966","phase":"PHASE3","title":"Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Yan Li","startDate":"2025-11-20","conditions":"Resistant Hypertension","enrollment":220},{"nctId":"NCT04840342","phase":"PHASE4","title":"MR Antagonist and LSD1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-02-03","conditions":"Hypertension, Mineralocorticoid Excess","enrollment":300},{"nctId":"NCT05103332","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2021-11-05","conditions":"Hypertension","enrollment":663},{"nctId":"NCT06730945","phase":"PHASE4","title":"Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After CABG","status":"WITHDRAWN","sponsor":"Ruijin Hospital","startDate":"2025-06","conditions":"Coronary Artery Bypass Graft Surgery (CABG), Radial Artery Grafts, Graft Failure","enrollment":""},{"nctId":"NCT02699645","phase":"PHASE3","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial","status":"COMPLETED","sponsor":"The George Institute","startDate":"2017-09-28","conditions":"Intracerebral Haemorrhage (ICH), Hypertension","enrollment":1671},{"nctId":"NCT05413057","phase":"","title":"An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2022-06-23","conditions":"Hypertension,Essential","enrollment":20000},{"nctId":"NCT02847338","phase":"PHASE4","title":"Comparison of Optimal Hypertension Regimens","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2016-11","conditions":"Hypertension","enrollment":940},{"nctId":"NCT04329806","phase":"PHASE1","title":"Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity","status":"TERMINATED","sponsor":"Italo Biaggioni","startDate":"2021-02-23","conditions":"Obesity-Associated Insulin Resistance","enrollment":10},{"nctId":"NCT05660135","phase":"","title":"Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-06-20","conditions":"Hypertension, Dyslipidemias","enrollment":4000},{"nctId":"NCT06796660","phase":"EARLY_PHASE1","title":"Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients","status":"NOT_YET_RECRUITING","sponsor":"Liu Zhanghong","startDate":"2025-09-01","conditions":"Renal Insufficiency, Chronic","enrollment":70},{"nctId":"NCT04111419","phase":"PHASE4","title":"Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-07-01","conditions":"Atrial Fibrillation, Hypertension","enrollment":1200},{"nctId":"NCT07116863","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Kyungdong Pharmaceutical Co., Ltd.","startDate":"2022-06-21","conditions":"Essential Hypertension","enrollment":286},{"nctId":"NCT03938389","phase":"PHASE4","title":"The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2020-02-25","conditions":"PreDiabetes, Impaired Glucose Tolerance, Obesity","enrollment":90},{"nctId":"NCT05331144","phase":"PHASE2","title":"Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)","status":"RECRUITING","sponsor":"Rong Zhang","startDate":"2022-10-25","conditions":"Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline","enrollment":180},{"nctId":"NCT06150560","phase":"PHASE3","title":"A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-04-01","conditions":"Coarctation of Aorta, High Blood Pressure","enrollment":120},{"nctId":"NCT03476616","phase":"PHASE4","title":"Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients","status":"COMPLETED","sponsor":"Hippocration General Hospital","startDate":"2018-09-01","conditions":"Hypertension, Obesity","enrollment":198},{"nctId":"NCT02373163","phase":"PHASE4","title":"INTERVENCION Trial","status":"COMPLETED","sponsor":"Prevencion","startDate":"2014-09-01","conditions":"Blood Pressure, High","enrollment":166},{"nctId":"NCT07064525","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension","status":"ENROLLING_BY_INVITATION","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2024-12-05","conditions":"Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure","enrollment":252},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT06942377","phase":"PHASE2","title":"Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-07-15","conditions":"Endometrial Cancer","enrollment":140},{"nctId":"NCT03354143","phase":"PHASE2","title":"Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-04-10","conditions":"Hypertension","enrollment":85},{"nctId":"NCT03553810","phase":"PHASE2","title":"Role of ARNi in Ventricular Remodeling in Hypertensive LVH","status":"COMPLETED","sponsor":"National Heart Centre Singapore","startDate":"2019-04-12","conditions":"Hypertensive Heart Disease","enrollment":80},{"nctId":"NCT06259175","phase":"","title":"Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2024-05-01","conditions":"Arterial Hypertension, HTN","enrollment":396},{"nctId":"NCT02904291","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Amlodipine","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2016-11","conditions":"Obesity, Morbid","enrollment":12},{"nctId":"NCT05288400","phase":"PHASE3","title":"Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.","status":"COMPLETED","sponsor":"Servier","startDate":"2018-05-14","conditions":"Essential Hypertension","enrollment":150},{"nctId":"NCT04518293","phase":"PHASE3","title":"Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension","status":"COMPLETED","sponsor":"George Medicines PTY Limited","startDate":"2021-07-09","conditions":"Hypertension","enrollment":1385},{"nctId":"NCT04518306","phase":"PHASE3","title":"Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension","status":"COMPLETED","sponsor":"George Medicines PTY Limited","startDate":"2021-06-14","conditions":"Hypertension","enrollment":755},{"nctId":"NCT06646354","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia","status":"ENROLLING_BY_INVITATION","sponsor":"Hyundai Pharm","startDate":"2025-04-22","conditions":"Hypertension, Primary Hypercholesterolaemia","enrollment":125},{"nctId":"NCT04158154","phase":"NA","title":"Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-02-01","conditions":"Hypertension","enrollment":21922},{"nctId":"NCT06625346","phase":"","title":"Clinical Response of EXTOR (Amlodipine/Valsartan) in Newly Diagnosed Hypertensive Patients.","status":"RECRUITING","sponsor":"The Searle Company Limited Pakistan","startDate":"2024-09-28","conditions":"Hypertension","enrollment":420},{"nctId":"NCT06495710","phase":"NA","title":"Arterial Stiffness and Blood Pressure","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-05-01","conditions":"Hypertension, Vascular Stiffness, Aging","enrollment":228},{"nctId":"NCT01806311","phase":"PHASE1","title":"Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2012-12","conditions":"Hypertension","enrollment":36},{"nctId":"NCT04179019","phase":"PHASE2","title":"Calcium Channel Blockade in Primary Aldosteronism","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-01","conditions":"Primary Aldosteronism, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)","enrollment":15},{"nctId":"NCT02988362","phase":"PHASE1","title":"Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2016-12-14","conditions":"Hypertension","enrollment":42},{"nctId":"NCT03946514","phase":"PHASE4","title":"Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-09-01","conditions":"Hypertension","enrollment":180},{"nctId":"NCT03683069","phase":"PHASE4","title":"Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-01-15","conditions":"Hypertension, Genetics Hypertension","enrollment":90},{"nctId":"NCT03264352","phase":"PHASE4","title":"Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes","status":"RECRUITING","sponsor":"XueQing Yu","startDate":"2018-02-01","conditions":"Diabetes Mellitus, Type 2, Adverse Event, Blood Pressure","enrollment":11414},{"nctId":"NCT04974138","phase":"PHASE4","title":"China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)","status":"RECRUITING","sponsor":"Shenzhen Ausa Pharmed Co.,Ltd","startDate":"2024-08-22","conditions":"Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L)","enrollment":32000},{"nctId":"NCT04974151","phase":"PHASE4","title":"China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype","status":"RECRUITING","sponsor":"Shenzhen Ausa Pharmed Co.,Ltd","startDate":"2024-08-22","conditions":"Hypertension, MTHFR 677 TT Genotype","enrollment":24000},{"nctId":"NCT06012487","phase":"PHASE1","title":"Correlates and Control of Blood Pressure Variability","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-05-01","conditions":"Blood Pressure Variability","enrollment":10},{"nctId":"NCT06826872","phase":"PHASE2","title":"Efficacy and Safety of SPC1001 in Patients With Essential Hypertension","status":"RECRUITING","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2024-06-12","conditions":"Hypertension, Essential, Cardiovascular Diseases, Cardiology","enrollment":252},{"nctId":"NCT05513937","phase":"PHASE4","title":"Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy","status":"COMPLETED","sponsor":"Menarini International Operations Luxembourg SA","startDate":"2022-05-12","conditions":"Hypertension","enrollment":301},{"nctId":"NCT06790927","phase":"NA","title":"Standardized Antihypertensive Treatment Protocol","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-02-24","conditions":"Hypertension","enrollment":400},{"nctId":"NCT05155137","phase":"PHASE3","title":"Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)","status":"RECRUITING","sponsor":"Hospital Moinhos de Vento","startDate":"2021-12-20","conditions":"Stroke, Cognitive Decline","enrollment":8518},{"nctId":"NCT06293261","phase":"","title":"Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2020-06-27","conditions":"Hypertension, Hypercholesterolemia","enrollment":5047},{"nctId":"NCT06780865","phase":"NA","title":"Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute of Hypertension","startDate":"2025-01-30","conditions":"Chronic Kidney Disease(CKD), Nocturnal Hypertension","enrollment":200},{"nctId":"NCT06771245","phase":"PHASE3","title":"A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-01-24","conditions":"Mild-to-moderate Essential Hypertension","enrollment":606},{"nctId":"NCT05089448","phase":"PHASE4","title":"Morning Versus Bedtime Dosing of Antihypertensive Medication","status":"RECRUITING","sponsor":"Yan Li","startDate":"2021-01-28","conditions":"Hypertension, Blood Pressure, Drug Use","enrollment":300},{"nctId":"NCT02893358","phase":"PHASE4","title":"Antihypertensive Treatment in Masked Hypertension","status":"COMPLETED","sponsor":"Yan Li","startDate":"2017-02-14","conditions":"Masked Hypertension","enrollment":320},{"nctId":"NCT03640312","phase":"PHASE2","title":"Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-08-30","conditions":"Hypertension","enrollment":62},{"nctId":"NCT06713785","phase":"PHASE4","title":"Personalised Electronic Record Supported Optimisation of Amlodipine for Patients With Hypertension","status":"WITHDRAWN","sponsor":"Queen Mary University of London","startDate":"2020-09-26","conditions":"Hypertension","enrollment":""},{"nctId":"NCT06424834","phase":"PHASE2, PHASE3","title":"Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-10-10","conditions":"Angina Pectoris, Microvascular Angina, Vasospastic Angina","enrollment":150},{"nctId":"NCT06704815","phase":"","title":"Observational Cohort Study Evaluating the Effectiveness of an Educational Program (NGAYDAUTIEN) in Combination With Perindopril and Amlodipine Single-Pill Combination in Hypertensive Patients naïve of Antihypertensive Treatments.","status":"COMPLETED","sponsor":"Servier Affaires Médicales","startDate":"2023-01-31","conditions":"Hypertension","enrollment":400},{"nctId":"NCT06523465","phase":"PHASE4","title":"Statin Combined with Amlodipine Treats Primary Aldosteronism","status":"RECRUITING","sponsor":"Third Military Medical University","startDate":"2024-09-10","conditions":"Primary Aldosteronism, Statin, Mineralocorticoid Receptor Antagonist","enrollment":180},{"nctId":"NCT02099123","phase":"PHASE4","title":"A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2015-07","conditions":"Independent Living, Disability Free Survival, Elderly","enrollment":9971},{"nctId":"NCT06282549","phase":"","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2022-06-08","conditions":"Essential Hypertension","enrollment":1219},{"nctId":"NCT02620163","phase":"PHASE3","title":"Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2015-12","conditions":"Hypertension","enrollment":381},{"nctId":"NCT03662620","phase":"PHASE1","title":"Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2018-10-05","conditions":"Hypertension","enrollment":67},{"nctId":"NCT04790279","phase":"PHASE4","title":"Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension","status":"COMPLETED","sponsor":"Prisma Health-Upstate","startDate":"2021-04-09","conditions":"Hypertension in Pregnancy","enrollment":175},{"nctId":"NCT05279807","phase":"PHASE4","title":"Effectiveness and Safety of Combination of Amlodipine and Zofenopril in Hypertensive Patients Versus Each Monotherapy","status":"COMPLETED","sponsor":"Menarini International Operations Luxembourg SA","startDate":"2021-10-15","conditions":"Hypertension","enrollment":277},{"nctId":"NCT05683301","phase":"PHASE4","title":"Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India","status":"COMPLETED","sponsor":"Centre for Chronic Disease Control, India","startDate":"2022-08-30","conditions":"Primary Hypertension","enrollment":1981},{"nctId":"NCT06618079","phase":"PHASE1","title":"Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huons Co., Ltd.","startDate":"2024-04-20","conditions":"Hypertension","enrollment":46},{"nctId":"NCT00834977","phase":"PHASE1","title":"Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-04","conditions":"Healthy","enrollment":48},{"nctId":"NCT00835367","phase":"PHASE1","title":"Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-03","conditions":"Healthy","enrollment":68},{"nctId":"NCT00841815","phase":"PHASE1","title":"Amlodipine 10 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-04","conditions":"Healthy","enrollment":28},{"nctId":"NCT00841542","phase":"PHASE1","title":"Amlodipine 10 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-04","conditions":"Healthy","enrollment":28},{"nctId":"NCT00157963","phase":"PHASE4","title":"Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-05","conditions":"Essential Hypertension","enrollment":174},{"nctId":"NCT00140959","phase":"PHASE4","title":"Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-01","conditions":"Hypertension","enrollment":120},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464},{"nctId":"NCT05820880","phase":"PHASE3","title":"Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2019-05-06","conditions":"Hypertension","enrollment":532},{"nctId":"NCT05479097","phase":"NA","title":"Feasibility Study of a Novel mHealth Application to Enable Community Health Workers to Manage","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2023-02-06","conditions":"Hypertension","enrollment":32},{"nctId":"NCT06487949","phase":"PHASE4","title":"Valsartan and Amlodipine in Blood Pressure Management: Fixed-Dose vs. Free Drug Therapy","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2022-12-01","conditions":"Hypertension","enrollment":114},{"nctId":"NCT04120753","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-08-26","conditions":"Hypertension, Dyslipidemias","enrollment":106},{"nctId":"NCT06465264","phase":"PHASE3","title":"To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2021-04-29","conditions":"Essential Hypertension","enrollment":499},{"nctId":"NCT01277822","phase":"PHASE4","title":"Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-05-30","conditions":"Hypertension","enrollment":334},{"nctId":"NCT06460896","phase":"NA","title":"Analysis of the Influence of Gastric By-Pass on the Pharmacokinetics of Common Drugs","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-09","conditions":"Bypass Bariatric Surgery","enrollment":64},{"nctId":"NCT05917275","phase":"PHASE4","title":"Multi-Omics to Predict the Blood Pressure Response to Antihypertensives","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2024-04-04","conditions":"Primary Hypertension","enrollment":96},{"nctId":"NCT06366386","phase":"","title":"Integrating Hypertension Management in DSD for HIV","status":"NOT_YET_RECRUITING","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2024-06-15","conditions":"Hypertension, HIV","enrollment":1100}],"_emaApprovals":[],"_faersSignals":[{"count":9,"reaction":"ASTHENIA"},{"count":9,"reaction":"HYPERGLYCAEMIA"},{"count":8,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":7,"reaction":"DIARRHOEA"},{"count":6,"reaction":"DRUG INEFFECTIVE"},{"count":6,"reaction":"DYSPNOEA"},{"count":6,"reaction":"FALL"},{"count":6,"reaction":"FATIGUE"},{"count":6,"reaction":"NAUSEA"},{"count":5,"reaction":"PRURITUS"}],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Amlodipine (Norvasc)","genericName":"Amlodipine (Norvasc)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amlodipine blocks calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced blood pressure. Used for Hypertension, Angina pectoris (chronic stable angina and vasospastic angina).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}